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Diagnosis and medical management
1.1  Background
chronic pancreatitis (cp) is defined as a continuing inflammatory 
disease of the pancreas characterised by irreversible morphological 
changes, often associated with pain and with the loss of exocrine 
and/or endocrine function which may be clinically relevant.1 alcohol 
is the predominant cause of cp in the western world, and is 
particularly prevalent in south africa2 (Table i). changing patterns of 
alcohol consumption and the availability of more sensitive diagnostic 
tests have led to the conclusion that cp is even more prevalent than 
previously suspected.3
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Background. chronic pancreatitis (cp) is defined as a continuing 
inflammatory disease of the pancreas characterised by irreversible 
morphological changes, often associated with pain and with the 
loss of exocrine and/or endocrine function that may be clinically 
relevant.  alcohol is the predominant cause of cp in the western 
world and is particularly prevalent in south africa, especially in 
the indigent patient. cp ranks high among intractable diseases 
of the gastrointestinal tract. The tendency for substance abuse in 
the alcohol-induced group poses major psychological and socio-
economic problems.
Objective. cp is a disease with significant clinical and pathological 
heterogeneity. level 1 evidence to support definitive guidelines 
for diagnosis, medical management and interventional therapy 
is lacking. Despite this paucity of robust scientific evidence, it is 
important to provide some assistance based on the best available 
evidence as to the current standard of care for cp in the south 
african context; this will aid all involved in the management of the 
disease, and includes clinicians, health care managers and funders.
Scope. The guidelines were developed as recommendations 
addressing the diagnosis, medical management and interventions, 
both endoscopic and surgical, for the management of a very complex 
and heterogeneous disease of the pancreas. The recommendations 
are particularly relevant in the south african context where the 
predominant patho-aetiological agents are alcohol-associated with 
smoking.
Recommendations. The guidelines provide clear recommendations 
regarding the diagnostic modalities available, both imaging (which 
includes Mri and endoscopic ultrasound (eus)) and pancreatic 
function tests. The section on medical management makes 
recommendations on the use of analgesics, enzyme replacement and 
other therapeutic options in the non-interventional management of 
the majority of patients with cp. The section on interventional 
procedures identifies the indications and options available for the 
interventional management of both uncomplicated and complicated 
cp. The role of endoscopic and surgical modalities is defined, but it is 
in this context especially that the best available evidence, combined 
with the experience of the group, influenced the recommendations 
put forward. Owing to the lack of evidence and the complexity of 
the disease, it is recommended that, where possible, cp is managed 
in the context of a multidisciplinary team.
Validation. The guidelines are based on best practice principles 
determined by the available evidence and the opinions of the 
group, which comprised 7 medical and surgical gastroenterologists 
with significant experience in dealing with patients with chronic 
pancreatitis in the south african context. The group convened 
between May 2009 and august 2010 under the auspices of the 
Hepato-pancreatico-Biliary association of south africa (HpBasa) 
and the south african Gastroenterology society (saGes), and the 
guidelines are the result of broad consensus within this group. The 
draft was presented to other experts in this field of endeavour to 
ensure broader participation and consensus.
Plans for guideline revision. HpBasa and saGes will publish a 
revised modification of the recommendations when new levels 1 
and 2 evidence data are published.
S Afr Med J 2010; 100: 845-860.
Guideline for the diagnosis and treatment of chronic 
pancreatitis
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The mechanism by which alcohol induces cp remains uncertain, 
but there is increasing evidence that damage to the pancreatic 
acinar cells occurs through the transient formation of fatty acid 
ethanol esters (Faees) which then leads to the so-called ‘necrosis-
inflammation-fibrosis’ sequence which may be self-perpetuating.4 
The entire pancreas is usually involved but, in about a third of cases, 
there is a distinct inflammatory mass in the head which often causes 
biliary and or duodenal obstruction. while in most cases there is 
progressive pancreatic duct dilatation associated with strictures, there 
is also a distinct subgroup with small duct disease associated with 
dense sclerosis. pancreatic stones in the calcific form of the disease 
are the result of decreased bicarbonate and water secretion on the one 
hand, and increased protein and calcium secretion with precipitation 
into the pancreatic duct system, on the other.
cp ranks high among intractable diseases of the gastrointestinal 
tract. The tendency to substance abuse in the alcohol-induced group 
poses major psychological and socio-economic problems. Two 
clinical groups are distinguished in the idiopathic and alcohol cp 
groups, namely (i) a mild form presenting with intermittent attacks 
and pain-free intervals, and (ii) those with severe disease.5,6 The 
former usually responds well to conservative treatment and tends to 
improve with time (so-called burn-out syndrome), while the latter is 
progressive and often comes to surgery for intractable pain with or 
without complications. The pathogenesis of pain remains an enigma, 
but there is general consensus that many factors are involved and that 
these may vary at different stages of the disease.
1.2  Diagnosis
although histology remains the gold standard against which all 
diagnostic approaches are judged, it is not practical in the clinical 
setting. Diagnosis currently depends on identifying clinical and 
morphological features which characterise the final common 
pathologic pathway of a variety of pancreatic disorders.
1.2.1.  Clinical manifestations
The primary clinical manifestations of cp are abdominal pain and 
pancreatic insufficiency, but patients may also present with the 
consequences of a complication.
Abdominal pain
The pain is typically epigastric in location, often radiates to the back, 
is frequently worse after meals and may be relieved by sitting upright 
or leaning forward. pain is usually but not invariably present; in one 
series, 20% of patients with cp presented with pancreatic exocrine or 
endocrine insufficiency, but no pain.5
Pancreatic exocrine insufficiency
clinically significant fat and protein deficiencies do not occur until 
over 90% of pancreatic function is lost.7 The clinical manifestations 
of fat malabsorption are steatorrhoea and flatulence. Malabsorption 
of fat-soluble vitamins and vitamin B12 may also occur, but clinically 
symptomatic vitamin deficiencies are rare.8
Pancreatic endocrine insufficiency
Overt diabetes mellitus (DM) typically occurs late in the course 
of the disease. a family history of type 1 or type 2 DM, early 
pancreatic calcification and distal pancreatectomy increases the risk 
of developing DM.9
Most patients with DM secondary to cp require insulin. Owing to 
the loss of glucagon-producing α-cells, such patients are at increased 
risk of spontaneous and treatment-related hypoglycaemia.
Complications
patients may occasionally present with complications of cp, such as 
duodenal obstruction, bile duct obstruction, pancreatic pseudocyst, 
pseudo-aneurysm, splenic vein thrombosis, pancreatic ascites, pleural 
effusion and pancreatic cancer.10
Recommendation
cp is more prevalent than previously suspected; unexplained 
abdominal pain, a history suggestive of maldigestion and DM 
represent end-stage, long-standing disease and should raise the 
possibility of the diagnosis.
1.2.2  Special investigations
cp represents a spectrum, ranging from end-stage disease with 
pronounced ductal and parenchymal changes, to mild disease 
requiring a combination of sophisticated imaging and functional 
studies to establish a diagnosis. The diagnosis can be made by 
morphologic criteria alone, or by a combination of morphologic 
and functional criteria. pancreatic function tests (pFTs) alone do not 
distinguish cp from pancreatic insufficiency without cp.
Imaging studies
 Despite the availability of numerous imaging modalities, early cp 
remains difficult to diagnose. The choice of imaging studies should 
be based on:
•   the available technology
•   the available skills
•   invasive nature of the investigation.
The choice of modality must involve the above factors. These 
guidelines are based on the best available evidence and best practice 
with respect to the role of the different diagnostic modalities.
X-rays of the abdomen
plain films reveal pancreatic calcification in only 30% of patients with 
cp. pancreatic calcification is most common in alcoholic cp and rare 
in idiopathic pancreatitis.
ultrasonography
Transabdominal ultrasonography (Tus) lacks sensitivity and 
specificity and is of limited value in diagnosing cp. its main value is 
to identify other causes of abdominal pain.
Computerised tomography (CT)
cT has a sensitivity of 75 - 90% and a specificity of 85%11-13 and is 
currently the screening test of choice. The past decade has seen major 
advances in cT technology; currently, multi-detector cT (MDcT) 
should be utilised.
cT findings suggestive of cp are gland atrophy, dilation of the main 
pancreatic duct (pD), ductal calculi, intra- or peripancreatic cysts, 
thickening of the peripancreatic fascia and splenic vein thrombosis. 
Focal or diffuse enlargement of the pancreas is occasionally seen, and 
intra-ductal papillary mucinous neoplasm (ipMN) should always be 
considered in the differential diagnosis. a hypo-dense mass in the 
head of the pancreas may simulate a carcinoma. Other cT findings 
suggestive of cp include heterogenous enhancement of the pancreas 
and the presence of a mass. Hypo-enhancement is indicative of 
fibrosis, whereas iso-enhancement suggests the absence of fibrosis.
Endoscopic ultrasound (EuS)
eus is increasingly being used to diagnose cp. Four parenchymal 
criteria (hyperechoic foci, hyperechoic strands, hypoechoic lobules, 
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cysts) and 5 ductal criteria (dilated main pancreatic duct, dilated 
side branches, main duct irregularity, hyperechoic duct margins, and 
stone) are generally accepted to be indicative of cp.14
However, published studies have been difficult to compare because 
of variations in the threshold and criteria required to diagnose cp.14-
19 interpretation is further complicated by the absence of a true gold 
standard, inter-observer variability and the lack of standardised 
terminology. The publication of minimum standard terminology 
(MsT)20 has been an advance, but there is still controversy on the 
definition of criteria.
a recent consensus conference on the eus criteria for a diagnosis 
of cp led to the publication of the so-called rosemont criteria 21 
which stratify cp into 4 groups consistent with cp, suggestive of cp, 
indeterminate for cp, and (lastly) normal. The criteria were ranked 
and weighted and, although not yet validated, are likely to improve 
particularly specificity21 (see addendum B).
MRI
Mri changes suggestive of cp are loss of signal intensity on fat-
suppressed T1wi and diminished contrast enhancement. Mrcp can 
delineate fluid-filled structures such as the main pancreatic duct and 
pseudocyst with good accuracy. as side branches are visualised in 
only 10 - 25% of cases,22,23 it is of limited diagnostic value in patients 
with early cp. at present, Mrcp does not have the sensitivity and 
specificity of ercp and therefore does not have a central role in 
assessing the pancreatic duct.
secretin-enhanced Mrcp has been shown to be very sensitive24 
and may be valuable in the very small group of patients in whom the 
above modalities have failed to confirm the suspected diagnosis of 
cp. However, secretin may not be readily available in south africa.
Endoscopic retrograde pancreatography (ERP)
erp is still valuable in the diagnosis of early cp because it accurately 
demonstrates the ductal changes as defined by the cambridge 
criteria25 (Table ii). This can be especially valuable when eus is not 
available, or the results of the Mrcp are equivocal.
Pancreatic function tests (PfTs)
pFTs have limited utility in the diagnosis of cp because of a lack of 
availability, poor patient tolerance and uncertain validation of the 
test results. Furthermore, they do not distinguish cp from pancreatic 
insufficiency without cp. pFTs are of value in diagnosing pancreatic 
insufficiency, in evaluating patients with cp and in providing a basis 
for rational treatment.
Direct PfTs
Direct pFTs involve stimulation of the pancreas by means of a meal 
or hormonal secretagogues, and subsequent collection and analysis 
of the duodenal fluid. The secretin test measures the ability of the 
ductal cells to produce bicarbonate, and the cholecystokinin (cck) 
tests the ability of the acinar cells to secrete digestive enzymes. The 
secretin-cck test provides simultaneous assessment of ductal and 
acinar secretory capacity. The lundh test duodenal radiograpic tube 
placement and sampling after a test meal is too complex and not 
consistently reproducible to be of value as a clinical test.
Indirect PfTs
indirect pFTs measure the consequences of pancreatic exocrine 
insufficiency and are more widely available than direct pFTs. 
However, they are less sensitive ,and their main utility is the diagnosis 
of advanced pancreatic exocrine insufficiency.
faecal fat
Quantitative measurement of faecal fat requires a high-fat diet, lack 
of exogenous enzymes and a 72-hr collection of stool, and is only 
sensitive for the diagnosis of advanced pancreatic insufficiency.26 
stool for acid steatocrit is an attractive alternative to this cumbersome 
test, as it not only compares favourably in terms of sensitivity and 
specificity, but is also inexpensive.27
faecal chymotrypsin and elastase-1
chymotrypsin and elastase-1 remain relatively stable during transit 
through the gastrointestinal tract. Measurement is easy and relatively 
inexpensive, but these tests lack sensitivity for mild to moderate 
pancreatic exocrine insufficiency and specificity in several non-
pancreatic gastrointestinal disorders.28,29
Pancreolauryl test (PlT)
The plT test involves the ingestion of fluorescein dilaurate and 
measurement of fluorescein in either serum or a 24-hr urine 
collection. as with other indirect tests, several non-pancreatic 
gastrointestinal disorders may reduce specificity.
Breath test
The breath test involves the oral administration of a 13c-labelled 
substrate which is hydrolysed within the bowel lumen in proportion 
to the pancreatic lipase activity. exhaled 13cO2 is measured by mass 
spectrometry or infrared analysis but, as with other indirect tests, it 
lacks sensitivity and specificity.
Recommendations
•    The diagnosis of cp can be made by morphologic criteria alone, 
or by a combination of morphologic and functional criteria; 
however, despite the availability of numerous imaging modalities, 
early cp remains difficult to diagnose.
•    X-rays of the abdomen and Tus have poor sensitivities and are not 
recommended for screening purposes. cT, as well as Mrcp, and 
increasingly eus, have become the screening methods of choice. 
There is still a role for erp. One or all of these investigations may 
be required to confirm the diagnosis.
•    pFTs do not distinguish cp from pancreatic insufficiency without 
cp and have a limited role in the diagnosis of cp.




whole gland without abnormal feature 
<3 abnormal branches
1 Mild >3 abnormal branches
2 Moderate abnormal main duct and branches
3 Marked as above with one or more of the 
following:
-   large cavities (>1 cm)
-   intraductal filling defects or calculi
-   ductal obstruction or strictures
-   gross irregularity
-   contiguous organ invasion
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1.3  Aetiology
Despite numerous attempts, the ideal disease classification system 
for cp remains elusive. One such classification is The M-aNNHeiM 
multiple-risk factor classification of cp.30
Pancreatitis with multiple-risk factors
Alcohol consumption
alcohol accounts for 60 - 70% of cp cases in the western world. The 
daily alcohol consumption at which persons are at risk of developing 
cp has not been established, but is estimated to be 60 - 80 ml/day. 
Gender and genetic and other co-factors may play pivotal roles, and 
the term ‘alcoholic pancreatitis’ therefore does not necessarily imply 
chronic alcoholism or harmful patterns of alcohol use. cigarette 
smoking appears to increase the risk as well as disease progression 
of cp.
There are several tools that may aid in identifying individuals with 
harmful patterns of alcohol consumption. The alcohol use Disorders 
identification Test (auDiT)31 provides a reliable assessment, but 
requires the participant to convert traditional measures into standard 
drinks. The paddington alcohol Test (paT)32 (Table iii) can be 
completed rapidly and compares well with auDiT.
Nicotine consumption
The odds ratio for smokers developing cp, compared with non-
smokers developing cp, ranges from 7.8 - 17.3, and the risk increases 
with the amount of tobacco smoked. Therefore, tobacco smoking 
should be considered an independent risk factor for the development 
of cp.33,34
Nutritional factors
The relationship between protein calorie malnutrition, 
hypertriglyceridaemia and other hyperlipidaemias and cp remains 
controversial.
Hereditary factors
Hereditary factors are believed to play a role in hereditary pancreatitis, 
familial pancreatitis, early-onset idiopathic pancreatitis, late-onset 
idiopathic pancreatitis and tropical pancreatitis. Mutations in the 
gene coding for cationic trypsinogen cause hereditary pancreatitis.35 
affected individuals usually develop symptoms before the age of 20 
years and are at markedly increased risk of developing pancreatic 
adenocarcinoma.
Mutations in the genes coding for cystic fibrosis trans-membrane 
conductance regulator (cFTr)36 and pancreatic secretory trypsin 
inhibitor (psTi or spiNk1)37 have been identified in patients with 
idiopathic cp.
Efferent duct factors
entities associated with obstructive cp include trauma, calculi, 
pseudocysts and tumours. it is controversial whether pancreas 
divisum and sphincter of Oddi dysfunction cause cp.
Immunological factors
autoimmune pancreatitis may be seen in isolation or in association 
with sjøgren syndrome, inflammatory bowel disease and a number of 
other auto-immune disorders.
serological findings of value in diagnosing autoimmune pancreatitis 
are hypergamma-globulinaemia, elevated igG, elevated igG4 and the 
presence of several auto-antibodies (anti-nuclear antibodies, anti-
lactoferrin antibodies, anti-carbonic anhydrase 11 antibodies and 
anti-smooth muscle antibodies).38 it is an important condition to 
recognise as the lesion responds to treatment with corticosteroids.
Miscellaneous and rare metabolic factors
chronic renal failure39 and hyperparathyroidism40 are recognised 
causes of cp, whereas the exact role of medications and toxins 
remains to be established.
Recommendations
•    a detailed history is of crucial importance as it may provide 
the clue to the aetiology. special attention should be paid to 
occupation and possible exposure to toxins, nutrition, and alcohol 
and tobacco consumption. The use of a validated tool aimed at 
identifying harmful drinking patterns is encouraged.
•    renal disease and hyperparathyroidism should be considered in 
the differential diagnosis and a history of auto-immune disease 
should raise the possibility of auto-immune pancreatitis.
•    a detailed family history should be obtained and, if an inherited 
disorder is suspected, the assistance of a genetic counsellor 
sought.
1.4  Medical treatment
Goals
Medical management of the patient with cp should focus on relieving 
symptoms and preventing the development of complications. There 
are 6 main goals that should be attained:
1.  cessation of alcohol consumption and cigarette smoking
2.   determine the cause of abdominal pain and attempt to relieve it
3.  treat pancreatic exocrine insufficiency
4.   detect and treat endocrine insufficiency early, before complications 
set in
Table III. Paddington Alcohol Test (PAT)
1.  Do you drink alcohol?
yes – go to 2.
No
2.  what is the most you drink in any one day?
(pub measures shown in brackets)
Beer/lager/cider              ……      pints (2)          ……    cans   (1.5)
strong beer/lager/cider   ……      pints (5)          ……    cans   (4)
wine                               ……      Glasses (1.5)    ……    Bottles (9)
Fortified wine                 ……      Glasses (1)       ……    Bottles (12)
spirits                              ……      singles (1)       ……     Bottles (30)
Total ____
3.  if this is more than 8 units per day for a man and 6 units per day 
for a woman, does this happen:
•  once a week or more = PAT +ve
•  or, if less frequent:
•  at least once a month = PAT +ve
•  less than once a month = PAT –ve (trumped by 4)
4.  Do you feel your current attendance is related to alcohol?
Yes = PAT +ve
No = PAT –ve 
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5.   nutritional support
6.   screening for pancreatic adenocarcinoma in cases of hereditary 
pancreatitis.
1.4.1  Behaviour modification
complete cessation of alcohol ingestion is recommended to reduce 
future morbidity and mortality. Furthermore, abstinence can in 
some cases lead to symptomatic improvement and pain relief, 
while ongoing alcohol ingestion contributes substantially to disease 
progression.41 However, cessation of alcohol does not necessarily halt 
disease progression. alcohol cessation is best achieved by enlisting 
the help of an alcohol dependency counsellor or psychologist. 
patients also need to be advised to stop smoking as this is a strong and 
independent risk factor for chronic alcoholic pancreatitis.42
Recommendations
all patients with cp should be advised to stop smoking and to abstain 
from alcohol consumption.
1.4.2  Treatment of abdominal pain
pain is the most common and most significant symptom of cp. The 
mechanism of pain is poorly understood and probably multi-factorial. 
several factors may exacerbate pain, and diagnostic tests may be 
necessary to search for these to institute appropriate treatment which 
may entail surgical or endoscopic intervention.43 Factors include 
pseudocyst formation, duodenal stenosis, biliary tract stricture, 
pancreatic cancer and peptic ulcer disease. if these are excluded, 
medical therapy is initiated using a sequential (step-up) approach. 
although the pain of cp may ‘burn out’ over time, particularly 
in alcohol-related disease, the duration over which this occurs is 
unpredictable.44 initial therapy consists of simple, non-narcotic 
episodic analgesia in the form of paracetomol or non-steroidal anti-
inflammatory drugs (NsaiDs), together with a low-fat diet.
patients who fail to respond could receive a 6-week trial of 
high-dose pancreatic enzymes (in uncoated tablet form).43-46 The 
recommended dose is equivalent to Viokase 16; 12 tablets per day, 
in divided doses with meals and snacks. However, the evidence to 
support this is poor; in addition, uncoated enzyme replacement 
therapy is not currently available in south africa.
a possible mechanism of pain relief from pancreatic enzyme 
replacement therapies is a reduction in pancreatic stimulation by 
food-induced cck. when exogenous pancreatic enzymes are taken 
with a meal, cck-releasing factors are degraded and cck release in 
response to a meal is reduced. However, clinical trials investigating 
this hypothesis have shown conflicting results.45,46 The majority of 
trials using enteric-coated preparations demonstrated no benefit, 
but this may reflect failure of the coated preparation to release the 
enzymes into the feedback-sensitive portion of the duodenum. in 
contrast, studies using non-enteric-coated tablets have demonstrated 
a reduction in pain compared with placebo. The effects of uncoated 
pancreatic enzymes are augmented by acid suppression therapy 
(either an H2 blocker or a proton pump inhibitor), which reduces the 
inactivation of the enzymes by gastric acid and increases the amount 
of protease to reach the duodenum.44,47 enzyme therapy appears to be 
most effective in ‘small-duct’ or ‘minimal change’ cp.48 Octreotide, 
while also effective in reducing pancreatic secretion, is not currently 
recommended for treating chronic pain.44
in subjects with refractory severe pain, narcotic analgesics may 
be required, starting with the least potent agents and progressing to 
more potent formulations as necessary. initially they should only be 
given on an ‘as needed’ basis. ideally, ongoing regular opioid analgesia 
is reserved for those in whom endoscopic or surgical therapies are 
not appropriate and symptoms are intractable. pethidine appears to 
be more addictive than other opiates and should be avoided wherever 
possible. Managing pain in cp is best done in conjunction with an 
experienced pain therapist who may wish to apply more specialised 
techniques such as intrapleural blocks.
Tricyclic antidepressants, selective serotonin re-uptake inhibitors 
and combined serotonin and norepinephrine re-uptake inhibitors 
will alleviate co-existent depression and may ameliorate pain and 
potentiate the effects of opiates. These agents may alter visceral and 
central nerve sensitisation, which are proposed mechanisms of pain 
in cp.48
antioxidants may be beneficial in reducing pain. a recent 
randomised, placebo-controlled trial of antioxidant supplementation 
in cp evaluated 147 patients over 6 months.49 The antioxidant 
supplementation consisted of daily doses of selenium, ascorbic 
acid, β-carotene, α-tocopherol and methionine. Overall, antioxidant 
supplementation led to significantly less painful days per month, 
a reduced need for oral analgesics and fewer hospitalisations. The 
beneficial effect of these antioxidants on pain relief was already 
significant at 3 months. whether these data are sufficient to 
recommend this intervention remains unclear.
Recommendations
•    chronic pain should be investigated to exclude pathologies which 
may be amenable to endoscopic or surgical therapy.
•    Medical treatment of pain should employ a sequential (step-
up) approach, commencing with simple, non-narcotic episodic 
analgesia (paracetomol or non-steroidal anti-inflammatory 
drugs), together with a low-fat diet.
•    if simple analgesia is insufficient for pain control, a 6-week trial of 
high-dose pancreatic enzymes (in tablet, uncoated form) may be 
appropriate, if this is available. acid suppression therapy should 
be given as an adjunct.
•    in subjects with refractory severe pain, narcotic analgesics may be 
required, starting with the least potent agents and progressing to 
more potent formulations as necessary.
•    Tricyclic antidepressants, selective serotonin re-uptake inhibitors 
and combined serotonin and norepinephrine re-uptake inhibitors, 
will alleviate co-existent depression and may ameliorate pain and 
potentiate the effects of opiates.
•    Managing pain in cp is best done in conjunction with an 
experienced pain therapist.
1.4.3  Treatment of pancreatic exocrine insufficiency
clinically significant malabsorption does not occur until more than 
90% of pancreatic function is lost.44 steatorrhoea usually occurs 
before protein deficiency.44 enteric-coated preparations are superior 
to uncoated therapy for the treatment of steatorrhoea, as lipase is 
protected from inactivation by gastric acid.50 clinical indications for 
initiating enzyme supplementation are frank steatorrhoea, weight 
loss or diarrhoea.
However, it has been shown that the sensitivity of clinical steatorrhea 
as a predictor of exocrine dysfunction is only 38%, suggesting that 
exocrine insufficiency will go undetected and untreated in many 
patients.27 as such, asymptomatic patients with cp may benefit 
from routine screening for sub-clinical exocrine insufficiency, and 
receive pancreatic enzyme replacement if identified. This approach 
is recommended by some experts in the field, but is not validated. a 
suitable option for screening is the stool acid steatocrit determined 
on spot samples which is a reliable, easy and inexpensive test which, 
when compared with 72-hr stool quantitative faecal fat, displayed a 
sensitivity of 100% and a specificity of 95%.51 an alternative method 
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of screening is the faecal elastase test, which is easy to perform, non-
invasive and convenient. unfortunately, these screening tests perform 
poorly in cases of mild to moderate pancreatic insufficiency.
Different formulations vary in lipase, protease, and amylase 
content. The aim is to provide at least 25 - 40 000 units of lipase 
per meal and 10 - 25 000 units of lipase with snacks. Because the 
cost is variable, one should consider the unit price of the enzyme 
supplement based on lipase content. The response to treatment is 
usually measured clinically by weight gain and improvement in 
symptoms, and the appropriate dose of enzyme replacement therapy 
needs to be titrated to maximise response. Despite an adequate 
clinical response, malabsorption may persist in some patients and 
higher doses (up to 60 000 units of lipase per meal) may be 
necessary.52 Because of the possible risk of fibrosing colonopathy 
with very high doses of enzyme replacement, a ceiling of 75 000 iu 
of lipase per meal has been recommended by some.50 it is essential 
that patients are counselled on the timing of enzyme ingestion in 
relationship to meals (enzymes should be ingested during a meal 
and not beforehand). patients who remain symptomatic despite 
compliance with maximal enteric-coated enzyme replacement would 
benefit from the addition of acid-suppressing medication.50 Other 
causes of diarrhoea should also be considered, in particular bacterial 
overgrowth, which is common in cp.53
Recommendations
•    pancreatic enzyme replacement therapy is recommended in 
patients with clinical features of exocrine insufficiency.
•    enteric-coated preparations are superior to uncoated therapy for 
the treatment of malabsorption.
•    The preferred dose is a minimum of 25 - 40 000 units of lipase per 
meal and 10 - 25 000 units of lipase with snacks.
•    The response to treatment is measured clinically by weight gain 
and improvement in symptoms.
•    The appropriate dose of enzyme replacement therapy needs to be 
titrated to maximise response.
•    patients who remain symptomatic despite compliance with 
maximal enteric-coated enzyme replacement would benefit from 
the addition of acid-suppressing medication.
1.4.4  Detection and treatment of endocrine 
insufficiency
up to 70% of patients with cp will eventually develop impaired 
glucose tolerance. The probability of endocrine insufficiency increases 
progressively within 10 years of disease onset.44 The diagnosis of 
endocrine insufficiency must be pursued early and aggressively by 
checking regular haemoglobin a1c (HBa1c) levels, fasting blood 
glucose or performing oral glucose tolerance testing. The optimal 
form of screening is debatable. recently, an international expert 
committee with members appointed by the american Diabetes 
association, the european association for the study of Diabetes, 
and the international Diabetes Federation recommended the use 
of HBa1c (at a level ≥6.5) rather than glucose for the diagnosis of 
diabetes.54 This is a significant departure from previous guidelines. 
advantages of HBa1c are that it can be done without fasting and 
also shows much lower variation within individuals, compared with 
blood glucose.
Most pancreatic diabetics whose glycaemic control is refractory 
to dietary manipulation will eventually require insulin. Oral 
hypoglycaemic agents have little role to play in advanced disease.55 
pancreatic diabetics are at higher risk of experiencing severe 
hypoglycaemia than other forms of diabetes as a consequence of 
impaired glucagon secretion, malnutrition and concomitant hepatic 
dysfunction owing to alcohol abuse. Hence, patients with one or 
more episodes of severe hypoglycaemia may benefit from relaxation 
of glycaemic targets.
long-term complications of pancreatic diabetes depend largely 
on the duration of the diabetes. life expectancy is reduced, mainly 
due to persistent alcohol and nicotine abuse (cardiovascular disease, 
malignant tumours). Treatment of pancreatic diabetes should aim at 
optimising glucose control to prevent complications, while avoiding 
hypoglycaemia.
Recommendations
•    The diagnosis of endocrine insufficiency must be pursued early 
and aggressively by checking regular HBa1c levels, fasting blood 
glucose or performing oral glucose tolerance testing.
•    Treatment of pancreatic diabetes should aim at optimising glucose 
control to prevent complications, while avoiding hypoglycaemia.
1.4.5  Nutrition
protein-calorie malnutrition is common in patients with cp and 
is often multifactorial, owing to abdominal pain, malabsorption, 
diabetes, altered gut motility and co-existent alcoholism.56 There is 
no specific ‘cp diet’. in general, small meals and a diet low in fat and 
high in protein and carbohydrates are recommended, especially in 
patients with steatorrhoea. The degree of fat restriction depends upon 
the severity of fat malabsorption. Generally, an intake <40 – 60 g per 
day is tolerated. specific recommendations include a daily diet of 2 
500 - 3 000 calories, protein intake of 1.0 - 1.5 g/kg/day and <30 - 40% 
of total calories consumed as fat per day.56
Medium chain triglycerides are directly absorbed by the small 
intestine without requiring lipase. They can be used to supplement 
lipids and caloric intake in patients with severe fat malabsorption, 
although their use is hindered by unpalatability.
Malabsorption of the fat-soluble vitamins (a, D, e and k) may 
also occur, although clinically symptomatic vitamin deficiency is rare. 
Vitamin B12 deficiency can also develop. Vitamin B12 is absorbed in 
the terminal ileum and complexed to intrinsic factor. when vitamin 
B12 enters the stomach, it binds haptocorrin (or r-protein). The 
haptocorrin is degraded in the small intestine by pancreatic enzymes, 
thus releasing B12 which then binds to intrinsic factor. in patients with 
pancreatic insufficiency, vitamin B12 can remain bound to haptocorrin 
and is not available for absorption by the terminal ileum. patients 
with ongoing alcohol abuse are also at risk of thiamine (vitamin B1), 
riboflavin (vitamin B2) and pyridoxine (vitamin B6) deficiencies. 
Vitamins should be replaced if serum levels indicate a deficiency.
Osteopaenia is a recognised complication of cp; a one-off 
assessment of bone mineral density (DeXa) should be considered.57
Recommendations
•    There is no specific diet that patients should be advised to follow.
•    small meals and a diet low in fat and high in protein and 
carbohydrates are advisable. The degree of fat restriction depends 
upon the severity of fat malabsorption and how it responds to 
enzyme supplementation.
•    Medium-chain triglycerides can be used to supplement lipid and 
caloric intake in patients with severe fat malabsorption refractory 
to enzyme replacement.
•    patients are at risk of fat-soluble vitamin (a, D, e and k) and B12 
deficiency.
•    Osteopaenia is a recognised complication of cp, and a one-
off assessment of bone mineral density (DeXa) should be 
considered.
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1.4.6  Screening for pancreatic adenocarcinoma
it is currently recommended that patients with hereditary pancreatitis 
enter a screening programme, beginning at the age of 40 years.58 
screening should be done annually. imaging options include 
eus, multiphasic helical cT or Mri/Mrcp. The use of ercp is 
controversial, given the invasive nature of this investigation. The 
imaging modality of choice will vary depending on the capabilities 
and preferences of the institution or hospital. The value of screening 
other forms of cp is unclear and not currently recommended. 
However, as cp (regardless of aetiology) is a known risk factor 
for cancer occurrence, any significant change in symptoms should 
prompt further investigation.
Recommendation
•    patients with hereditary pancreatitis should enter a screening 
programme for adenocarcinoma, beginning at the age of 40 
years.
•    routine screening of other forms of cp for adenocarcinoma is not 
currently recommended, but any significant change in symptoms 
should prompt further investigation.
1.4.7  Autoimmune chronic pancreatitis
special mention must be made of auto-immune cp, as alternative 
therapies – notably corticosteroids – may be effective treatment. it 
was felt that this topic was a distinct entity and beyond the scope of 
this guideline.
2.  Interventional procedures
while the majority of patients with cp can be managed adequately 
with medical therapies, surgical and non-operative interventional 
procedures can play an important role in selected cases with 
intractable pain, in uncomplicated disease and in the management 
of complications. The decision to intervene should be based on a 
multi-disciplinary approach, preferably in a centre experienced in the 
medical and surgical management of pancreatic disease.
2.1  Management of pain in uncomplicated 
disease
The decision to intervene should be carefully weighed up against the 
risk of complications and long-term sequelae of the procedure. it is 
important to stress that the indications for seemingly less invasive 
non-operative interventional procedures should not be different to 
that of surgery. Other causes of foregut pain should be excluded by 
appropriate investigations. intervention should be considered when a 
stepwise approach to pain control (see par. 1.4.2) has failed to achieve 
adequate pain control, and when there is concern about opioid 
dependency, impaired quality of life and inability to work.
The timing of surgery is particularly problematic. it is often 
difficult to find a balance between early operations, which may 
compromise pancreatic function, and the risk of opioid addiction 
when conservative treatment is prolonged.59 interventions should 
be considered if there is an escalated need and/or continuous usage 
of opioids. patients must be carefully counselled on the risks of 
the procedure and informed that their pain may not be relieved 
satisfactorily. it should also be emphasised that interventions are 
unlikely to improve or prevent exocrine and endocrine insufficiency.
Principles of interventional procedures
it is generally accepted that the pathogenesis of pain in uncomplicated 
cp is multi-factorial59 and that it is difficult to determine which 
of these, or combinations thereof, are pertinent in an individual 
patient. Nonetheless, interventional procedures are either directed 
at addressing the morphological changes of the pancreatic duct 
system (strictures and stones), and inflammatory changes of the 
parenchyma, or by neurolysis of its nerve supply.
2.1.1  Endoscopic treatment
endoscopic treatment addressing strictures and stones with or 
without extracorporeal shock wave lithotripsy (eswl) has been 
utilised with increasing frequency in specialised gastrointestinal 
units. success rates varying from 50 - 85% at 15 - 25 months have 
been reported.60 eswl can produce equally good results when 
compared with a combination of eswl and endoscopic treatment, 
with a significant reduction in cost as shown in one trial.61 in two 
rcTs,62,63 surgery produced superior results to endoscopic therapy, 
but the interpretation of the results was hampered by the small 
percentage of patients eligible for the study and, in one report,62 
surgery was only superior to endoscopic therapy in the intention-to-
treat group, and not in those patients who were randomised.
endoscopic treatment requires a high level of endoscopic expertise 
and is labour-intensive. Furthermore, it carries risks such as bleeding, 
perforation and sepsis. There is also concern about ductal and 
parenchymal injury with long-term stenting.
Recommendation
while endoscopic treatment provides inferior results to surgery 
for long-term pain control in uncomplicated cp, it would seem 
reasonable to offer this less invasive, but technically-demanding 
treatment option, in the small sub-group of patients with localised 
strictures and stones in the main pancreatic duct. long-term stenting 
should be avoided, and the role of eswl outside specialised centres 
remains uncertain.
2.1.2  Neurolysis
The results of celiac plexus block using a variety of neurolytic agents 
(e.g. ethanol or phenol) have been disappointing.64  The procedure 
also carries risks related to the necrosing effects of the agents. eus-
guided neurolysis is purported to be safer; a meta-analysis on pain 
control showed a 60% response rate.65 However, there is no indication 
that long-term results are better than those of other methods.66
with the advent of minimal access surgery, there has been renewed 
interest in thoracoscopic splanchnicectomy. There is a belief that 
this form of neurolysis, when performed bilaterally, provides a 
more complete interruption of the sympathetic nerves that transmit 
the afferent paths of pancreatic pain. But, as in the case of coeliac 
plexus blocks, long-term results are disappointing, particularly in 
young patients (<45 years) and in those who had previous pancreatic 
surgery.67 Open surgical denervation procedures are no longer 
performed.
Recommendation
Neurolysis has no place in the long-term control of pain in cp.
2.1.3  Surgery
surgery in one form or another provides the best chance for long-term 
pain relief in uncomplicated disease and can also address associated 
complications such as bile duct and or duodenal obstruction. 
surgery is also indicated in cases where malignancy is suspected or 
cannot be excluded. These are complex procedures and should only 
be undertaken by surgeons with specialised training in pancreatic 
surgery working in a multi-disciplinary environment. in addition, 
all other treatment options should have been exhausted or be 
inappropriate. surgery should only be undertaken once patients 
have been carefully evaluated for co-morbid diseases and when the 
morphological changes of the pancreas have been clearly delineated 
by modern cross-sectional imaging. it is particularly important to 
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determine the presence of associated portal hypertension which may 
preclude surgical intervention.
Numerous surgical procedures have been devised since Gould68 
successfully removed calculi from wirsung’s duct in 1898. Table iV 
lists the most commonly performed operations performed today and 
indicates their selection based to a large extent on parenchymal and 
pancreatic ductal morphological changes of the pancreas. surgery 
should be carried out with minimal morbidity and mortality and with 
maximum preservation of pancreatic function. To this end, there has 
been a paradigm shift away from the standard resection procedures, 
such as the classic whipple’s (cw) and pylorus preserving pancreatico-
duodenectomy (pppD), to organ-preserving resection operations 
such as the Frey and Beger operations and hybrid modifications. a 
detailed review of the results of the various surgical procedures is 
beyond the scope of these guidelines; but, based on reviews on the 
subject and rcTs,69-72 the following conclusions can be drawn:
•    Classic Whipple’s operation (CW) is associated with a higher 
morbidity and mortality, greater weight loss and poorer quality 
of life (QOl) compared with the organ-preserving operations. 
The operation is now reserved for patients with a suspected 
malignancy.
•    Distal pancreatectomy is indicated in carefully selected patients 
where the disease is confined to the distal pancreas with isolated 
ductal obstruction, with or without a pseudocyst.73 Extended 
distal pancreatectomy (>80%) for diffuse disease is associated 
with poor long-term outcome in terms of pain control, and is 
associated with a high incidence of diabetes.74 likewise, total 
pancreatectomy should only be considered in rare cases after 
previous failed operations. Islet Island cell transplantation, to 
address the problem of diabetic control in this setting, has been 
performed by a few centres with variable results.75
•    Pylorus preserving pancreatico-duodenectomy (PPPD). studies 
comparing pppD with the Beger operation have produced 
conflicting results in terms of morbidity, pain relief and functional 
outcome, but on balance favour the latter. However, the earlier 
functional advantages of the Beger operation were no longer 
evident in one long-term follow-up study.76 The results were 
more clearly in favour of the Frey procedure when this was 
compared with pppD in two rcTs.77,78 pppD is mainly reserved 
for cases with suspicion of malignancy, or selected patients with 
an inflammatory mass in the head of the pancreas associated with 
biliary and duodenal obstruction.
•    Organ-preserving operations. The most commonly performed 
preserving operations are the Frey and Beger procedures and 
their hybrid modifications. in one rcT comparing these two 
operations,79 strate et al. showed no difference in their long-
term outcome. The Frey operation is currently the most widely-
performed, duodenal-preserving resection operation for patients 
with an inflammatory mass in the head of the pancreas associated 
with a dilated pancreatic duct system, while the Beger procedure 
is reserved for non-dilated ducts. alternatively, izbicki et al.80 
introduced a modified V-shaped excision of the ventral pancreas 
with a pancreatico-jejunostomy for ducts <3 mm in size, with 
seemingly equally good results.
•    Standard pancreatico-jejunostomy (Partington and Rochelle). 
This operation has a limited role and may be indicated in patients 
with a dilated pancreatic duct without an inflammatory mass in 
the head of the pancreas. it may also be indicated when there is an 
associated pseudocyst.81
The results of the above operations69 are similar, but the trend is 
in favour of organ-preserving operations. in expert hands, operative 
morbidity is about 30% and mortality <1%. long-term (5 - 7 years) 
pain relief varies from 80 - 90%, and new-onset diabetes occurs in 
one- third, and steatorrhoea in two-thirds, of patients. The functional 
abnormalities identified in long-term follow-up are a reflection of 
the natural history of the disease, rather than the outcome from an 
individual operation.76 QOl is improved in most patients, with 36 - 
75% returning to work. some reports suggest that long-term QOl 
after surgery remains poor due to the lifestyle and co-morbidities, 
particularly after resection operations.82
life expectancy is shortened in patients with cp, and late mortality 
(10 years) after surgery occurs in about a third of patients. pancreatic 
cancer is the cause of death in up to 10% of cases. Deaths due to 
smoking-related diseases are also common, as are deaths due to the 
complications of diabetes in the indigent patient.
Recommendation
in carefully selected cases, surgery has an important role to play in 
the management of intractable pain in cp. The choice of surgery 
is governed to a large extent by the size of the pancreatic duct and 
the presence or absence of an inflammatory mass in the head of the 
pancreas. The principles of surgery are to minimise morbidity and 
mortality and to preserve exocrine and endocrine pancreatic function. 
The classic whipple’s operation has now been superseded by organ-
preserving resection. surgery should be performed in specialised 
centres, with the emphasis on a multi-disciplinary approach.
2.2  Complications in CP
2.2.1  Pseudocysts (pancreatic fluid collections) and 
ascites
pancreatic fluid collections (or pseudocysts, to which they are more 
commonly referred) occur in 30 - 40% of patients with cp. The 
pathogenesis is thought to be due to two main processes as described 
by D’egidio and schein.83 ‘retention cysts’ may be the result of ductal 
obstruction, while pancreatic necrosis with ductal disruption and leak 
of pancreatic fluid may develop during an episode of acute on chronic 
pancreatitis. a clear distinction should be made between post-
necrotic fluid collections following acute necrotising pancreatitis, 
and those occurring in patients with established cp. The former are 
usually immature collections containing necrotic material, whereas 
the latter consists mainly of pancreatic fluid, rich in amylase. The 
pseudocysts in cp are often intra-pancreatic (mostly located in the 
head) or confined to the lesser sac.84 pancreatic ascites occurs when 
there is rupture of a pseudocyst or duct into the peritoneal cavity.
pseudocysts in cp present with pain or obstruction to neighbouring 
structures, causing mostly biliary or gastric outlet obstruction. They 
can also present with erosion into blood vessels and the formation of 
Table IV. The most common surgical options for CP
procedures indications
resection:
-  pancreaticoduodenectomy -  suspicion of malignancy
-  distal pancreatectomy -   disease confined to the body 
and tail of the pancreas
Duodenal-preserving 
resection of the head of the 
pancreas 
-   inflammatory mass of the 
head of the pancreas, with or 
without a dilated pancreatic 
duct
pancreatico-jejunostomy -   dilated pancreatic duct 
without inflammatory mass in 
the head of the pancreas.
GuIDElINES
855December 2010, Vol. 100, No. 12  SAMJ
a pseudo-aneurysm which can present as GiT bleeding when there is 
communication with the pancreatic duct (haemosuccus pancreas) or 
bleeding into the pseudocyst. pseudocysts can also become infected, 
but this occurs less often than in cases with acute post-necrotic fluid 
collections.
cT scanning remains the imaging modality of choice, but Mri and 
Mrcp are gaining in popularity. The role of ercp as a diagnostic 
modality is waning as the information required can be determined 
from Mrcp. it is of paramount importance to differentiate 
pseudocysts from cystic tumours of the pancreas which are now more 
readily diagnosed with modern cross-sectional imaging. a review on 
how to differentiate pseudocysts from cystic neoplasm is beyond the 
scope of these guidelines, but is based on clinical and morphological 
features and cyst fluid analysis. a cystic neoplasm should be strongly 
suspected in patients without a history of alcohol abuse, and/or 
previously confirmed attacks of pancreatitis – especially in middle-
aged women.
The indications for the treatment of pseudocysts are the presence 
of symptoms or complications. it is recognised that larger pseudocysts 
(>6 cm) will be symptomatic more often and, as such, will require 
treatment more often, but size alone is not necessarily an indication 
for treatment. There is very little level 1 evidence to support any 
particular treatment option in the management of pseudocysts. 
However, there is growing consensus to support endoscopic drainage 
with or without eus as the first line of treatment. The procedure has 
a high success rate, is a lesser procedure than surgery and has a good 
safety record.85 eus-guided drainage has broadened the scope of 
endoscopic drainage86-88 and is purported to increase the safety of the 
procedure  – particularly in the presence of portal hypertension. The 
most common endoscopic drainage approach is transduodenal or 
transgastric, but the trans-papillary approach is also used and is an 
alternative method in cases unsuitable for the former.
simple aspiration or the placement of external drainage catheters 
is usually inappropriate for pseudocysts in cp owing to a high failure 
rate and potential risk of a persistent external fistula, as most of these 
collections communicate with the pancreatic duct. in selected cases, 
it may be useful as a temporary measure in patients with very large 
and symptomatic lesser sac pseudocyst.
in selected patients, percutaneous transgastric drainage placement, 
combined sometimes with endoscopic therapy, may be a useful 
approach to managing the pseudocyst.
Surgery is indicated in cases unsuitable for non-operative 
drainage, failures after endoscopic treatment and in the presence 
of life-threatening complications. surgery may also be the preferred 
treatment in cases with other associated complications such as biliary 
and duodenal obstruction, and when there is gross pancreatic duct 
dilatation, with or without an inflammatory mass in the head of the 
pancreas.59
in the main, the choice of surgical procedures will be dictated by 
the location of the pseudocyst and its proximity to the bowel wall. 
cyst drainage procedures were commonly used in the past. in this 
procedure, lesser sac collections are drained via the posterior wall 
of the stomach (cyst-gastrostomy) and those close to the duodenum 
by way of a cyst-duodenostomy or roux-en-y cyst-jejunostomy. The 
disadvantage of these procedures is that when there are associated 
underlying ductal and parenchymal abnormalities, patients may 
continue to experience ongoing pain. as such, organ-preserving 
procedures (i.e. Frey procedure) may be the preferred treatment. 
Distal pancreatectomy is indicated in cases with segmental disease in 
the body/tail of the pancreas and an associated pseudocyst,73 and in 
cases with a suspicious cystic tumour.
2.2.2  Complications associated with pseudocysts
Infection
while percutaneous drainage is generally recommended for infected 
pseudocyst, there is a growing trend to treat endoscopically those 
occurring in cp. surgery is indicated if non-operative treatment fails, 
or is not available.
Pancreatic ascites and pleural effusion
No clear guidelines can be derived from current publications on this 
rare complication. conventional treatment strategies include bed rest 
with nutritional support by parenteral/enteral feeding, paracentesis, 
and the use of somatostatin analogues. However, there is no objective 
evidence that any of these treatment modalities, including somatostatin 
analogues, have a major effect on the natural history, bearing in mind 
that the ascites or pleural effusion will resolve spontaneously in a 
substantial percentage of cases. prolonged conservative treatment 
with parenteral nutrition should be avoided as this increases the risk 
of sepsis.89 endoscopic intervention (papillotomy/stenting) with the 
aim of sealing off the leak and overcoming a distal obstruction should 
be considered early after initial supportive intravenous nutritional 
therapy. The success rate varies in published series, but may be 
high in skilled hands.90 surgery to address the leak and underlying 
pathology is now reserved for failures of endoscopic treatment.
Haemorrhage
Haemorrhage associated with cp may be due to analgesic-induced 
peptic ulceration, false aneurysms related to pseudocysts, or gastric 
varices secondary to segmental portal hypertension. Bleeding from a 
false aneurysm can in the majority of cases be treated with selective 
angiographic embolisation.91 when surgery is required, the procedure 
should be aimed at vascular control and not definitive treatment of 
the cp, unless the bleeding site is in the tail of the pancreas, in 
which case a distal pancreatectomy is indicated. Most patients with 
segmental portal hypertension will not bleed from gastric varices. 
a splenectomy should therefore only be performed when there is 
proven bleeding from gastric varices.
Recommendations
•    Only symptomatic pseudocyst should be treated, and size alone is 
not an indication to intervene.
•    The lack of distinction between acute post-necrotising pseudocysts 
from those occurring in cp in published series has made it 
difficult to recommend a particular interventional procedure.
•    in suitable cases, endoscopic treatment is the preferred treatment, 
the scope of which has increased when performed under eus 
guidance.
•    surgery is reserved for cases unsuitable for endoscopic drainage 
and failures with recurrence of pain, with or without recurrence 
of the pseudocyst.
•    in selected cases, the underlying pancreatic pathology should 
be addressed with appropriate combined resection and drainage 
procedures.
•    Haemorrhage from false aneurysms related to pseudocyst is best 
controlled by selective angiographic embolisation.
•    endoscopic intervention is indicated in patients with persistent 
pancreatic ascites/pleural effusion.
2.2.3  Duodenal obstruction
The management of patients with persistent duodenal obstruction 
will depend on the underlying cause. Drainage of a large pseudocyst 
by whichever means would resolve the problem but, when it is 
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due to residual fibrosis, some form of surgical intervention would 
be required. in some instances, mobilisation of the duodenum 
by way of a kocher’s manoeuvre would suffice. it is very difficult 
to find consensus on the best surgical procedure. There may be 
situations were a duodeno-duodenostomy or a duodeno-jejunostomy 
or a gastro-jejunostomy may be appropriate. when associated with 
a biliary obstruction and an inflammatory mass in the head of the 
pancreas, consideration should be given to performing a pylorus-
preserving pancreaticoduodenectomy.
2.2.4  Bile duct obstruction
Obstruction of the biliary tree is common during the advanced 
stages of cp, particularly when associated with calcification and an 
inflammatory mass in the head of the pancreas. Obstruction can 
be caused by oedema, an intrapancreatic pseudocyst or fibrosis. 
The natural history of the obstruction will vary according to the 
underlying pathology. The clinical presentation varies from an 
incidental discovery to overt jaundice, with or without associated 
cholangitis. Jaundice that occurs during acute exacerbations is 
often transient and may resolve completely without requiring 
intervention. The risk of developing secondary biliary cirrhosis is 
low, particularly in non- jaundiced patients who present with raised 
alkaline phosphatase (alp) or a dilated biliary system on imaging.92 




a disproportionately-raised alp and gamma GT is typically seen 
in patients with low-grade obstruction. in jaundiced patients, liver 
function tests frequently improve, which is useful to distinguish 
benign from malignant obstruction. CA 19-9 may be elevated in cp 
with biliary obstruction, although levels seldom exceed 100 - 120 u/
ml.93 
Imaging
while ultrasound is usually the first imaging modality to identify 
biliary obstruction, cT scan is required to define the nature and 
extent of the disease, and to help differentiate cp from a pancreatic 
cancer. Mrcp is the preferred imaging to delineate the bile duct 
stricture and pancreatic duct anatomy. although a smooth tapering 
of the distal bile duct is suggestive of cp, this finding is not reliable 
enough on its own to distinguish it from a carcinoma. ercp is 
reserved in the main when intervention is required. endoscopic 
brush cytology has a very good specificity but poor sensitivity in the 
diagnosis of malignancy, yet is a valuable adjunct to diagnosis and 
should be considered in patients undergoing erp.94
Management
Management is largely dictated by the clinical presentation and 
morphological changes of the pancreas. clinical factors to consider 
include the presence and severity of associated pain, the occurrence 
of jaundice and duration thereof, concern about malignancy and 
co-morbid diseases. surgical strategy will depend on the presence of 
an inflammatory mass in the head of the pancreas and the degree of 
bile duct and pancreatic duct dilatation.92
Recommendations
•    patients with asymptomatic bile duct strictures, including those 
with an isolated raised alp, should be treated conservatively with 
regular follow-ups.
•    endoscopic interventions and stenting should be discouraged, as 
this may cause secondary infection, particularly when the stents 
occlude. There is no need to perform regular liver biopsies to 
detect the development of secondary liver cirrhosis in this group 
of patients. 
•    patients who present with jaundice should initially be treated 
conservatively, unless associated with cholangitis, when a 
temporary stent should be placed. if jaundice resolves, no further 
intervention is required, but the patient will require follow-ups.
•    a surgical bypass, preferably a hepatico-jejunostomy, is acceptable 
in the relatively uncommon scenario when jaundice persists in the 
absence of any other sequelae of the cp.
•    a Frey procedure with a hepatico-jejunostomy is the preferred 
operation when there is an inflammatory mass in the head of 
the pancreas associated with a dilated pancreatic duct. in the 
absence of a dilated duct, a pylorus-preserving pancreatico-
duodenectomy could be performed, as well as in those patients 
where a malignancy is suspected.
•    The current recommendation for stenting is in patients who 
present with cholangitis and those unfit for surgery owing to 
severe co-morbid diseases. The indications for stenting may 
expand with the development of removable expandable stents 
in those patients where jaundice is the predominant clinical 
presentation.
3.  Summary and conclusion
alcohol is by far the most common causative agent in the development 
of cp, and the prognosis is therefore to a large extent dependent on 
abstinence, together with cessation of smoking. while the natural 
history is usually characterised by marked progression of the disease 
associated with increasing severity in pain with the associated risk of 
narcotic dependency, there is a subgroup of patients where the disease 
runs a more benign course. endocrine and exocrine insufficiency 
is a late manifestation. in patients with progressive disease, life 
expectancy is shortened by associated pancreatic complications, 
malnutrition and diseases related to smoking.
The mainstay of treatment is abstinence from alcohol and smoking, 
with careful pain control that requires close monitoring to reduce the 
risk of opioid dependency. During the late stages of the disease, 
medical treatment emphasis may shift to include diabetic control, 
exocrine pancreatic replacement therapy and nutritional support.
The role of endoscopic therapy for pain control in uncomplicated 
disease is limited, while organ-preserving operations in carefully 
selected patients with intractable pain may provide long-term relief. 
However, in selected cases, endoscopic therapy has become the 
treatment of choice for complicated disease, especially pseudocysts.
cp is a complex disease which requires a multi-disciplinary 
approach by specialists in this field, particularly when interventional 
procedures are to be considered for intractable pain and other 
complications.
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Addendum A
Rosemont criteria: Consensus-based parenchymal features of CP21






≥2 mm in length and 
width that shadow
Major a 1 parenchymal-based 
calcifications
lobularity well- circumscribed, 
≥5 mm structures, 

















foci ≥2 mm in both 





with or without 
septations
yes 4 pseudocyst
stranding Hyperechoic lines 
≥3 mm in length in 
at least 2 different 
directions with 
respect to the image 
plane
yes 5 unknown
Rosemont criteria: Consensus-based ductal features of CP21
feature Definition Major criteria Minor criteria Rank
Histological 
correlation
MpD calculi echogenic 
structure(s) within 
MpD with acoustic 
shadowing
Major a 1 stones
irregular MpD 
contour
uneven or irregular 
outline and ectatic 
course
yes 2 unknown
Dilated side branches ≥3 tubular anechoic 
structures each 
measuring ≥1 mm in 
width, budding from 
the MpD
yes 3 side-branch ectasia
MpD dilation ≥3.5 mm body or 
>1.5 mm tail




structure >50% of 
entire MpD in the 
body and tail
yes 5 Ductal fibrosis
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